Seoul, Korea, South, March 20, 2015 --(PR.com
)-- GTL Partners, an international patent broker, has just obtained exclusive rights to sell and/or license a new patent that can be used for the prevention or treatment of the Hepatitis C Virus.
The new U.S. patent No. 8,865,659, titled “Compositions for Prevention or Treatment of Hepatitis C Virus Containing Ginsenoside RG3 as an Active Ingredient,” describes the formula needed in order to produce a safe and effective compound for treating hepatitis C by using ginsenoside Rg3, which is extracted from the ginseng root. The composition of this invention can be used in numerous areas as medical/pharmaceutical or health food products and its pharmaceutically acceptable salts may be administrated in various oral and non-oral formulations.
Around 3% of the world’s population, about 200 million people, currently have the hepatitis C virus (HCV). A significant number of people who have chronic HCV infection develop liver cirrhosis or liver cancer, and 350,000 to 500,000 people die each year from HCV related liver diseases according to the World Health Organization. The global HCV market is expected to reach USD 15 billion in 2015 and USD 18.6 billion by Morgan Stanley’s prediction.
The current standard HCV treatment using Sovaldi or Harvoni, which are made of chemical compounds, usually have a 12 to 24 week therapy schedule and have a price tag of up to $1,000 a pill. Other treatments for HCV may cost less but come with some serious side-effects, such as anemia, neutropenia, and even birth defects according to the U.S. Department of Veterans Affairs.
This patent on the other hand, uses all natural ginsenoside Rg3 isolated from red ginseng for preventing and treating the hepatitis C virus infection. Ginseng as a traditional herbal medicine has been widely used in Asian medicine historically and ginsenosides are pharmacologically active natural constituents of ginseng. Prof. Jae-Young Jang, the developer of this new HCV treatment patent, explained the need for his invention, “While current standard HCV treatments inhibit reproduction of the hepatitis C virus, this technology inhibits excretion of the virus as well and at the same time decreases serious toxic side effects while also increasing the immunity and survival rate.” This Rg3 based treatment is expected to be easily accessible, have a lower cost, a shorter treatment period and minimum side effects compared to the current leading HCV treatments.
GTL Partners is a leading Technology & IP Asset Management company focused on Technology & IP advisory, transactions, business development, and investment banking services. For more information about GTL Partners please go to www.gtl.partners
Adam Bieniek – Manager